Recently, biomarkers related to bone metabolism, such as IGF-1 and osteocalcin, have shown significant potential in the early diagnosis, subtype classification, and assessment of therapeutic efficacy in girls with CPP (28, 29, 30). The gene discussed is IGF1; the disease is central precocious puberty.